Neuroleptic malignant syndrome (NMS)

Also known as: Neuroleptic Malignant Syndrome / Malignant neuroleptic syndrome / Neuroleptic malignant syndrome (disorder) / Neuroleptic malignant

Drug	Drug Name	Drug Description
DB01200	Bromocriptine	A dopamine D2 receptor agonist used for the treatment of galactorrhea due to hyperprolactinemia and other prolactin-related conditions, as well as in early Parkinsonian Syndrome.

Drug	Drug Name	Target	Type
DB01200	Bromocriptine	Dopamine D2 receptor	target
DB01200	Bromocriptine	Cytochrome P450 3A4	enzyme
DB01200	Bromocriptine	5-hydroxytryptamine receptor 1D	target
DB01200	Bromocriptine	Alpha-2A adrenergic receptor	target
DB01200	Bromocriptine	Dopamine D3 receptor	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 1A	target
DB01200	Bromocriptine	Alpha-2C adrenergic receptor	target
DB01200	Bromocriptine	Alpha-2B adrenergic receptor	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 2B	target
DB01200	Bromocriptine	Dopamine D4 receptor	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 2A	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 1B	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 2C	target
DB01200	Bromocriptine	Dopamine D5 receptor	target
DB01200	Bromocriptine	Dopamine D1 receptor	target
DB01200	Bromocriptine	Alpha-1A adrenergic receptor	target
DB01200	Bromocriptine	Alpha-1B adrenergic receptor	target
DB01200	Bromocriptine	Alpha-1D adrenergic receptor	target
DB01200	Bromocriptine	5-hydroxytryptamine receptor 7	target
DB01200	Bromocriptine	P-glycoprotein 1	transporter

Drug	Drug Name	Phase	Status	Count